Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Hashimoto, Mamoru; Nakayama, Takahito; Fujimoto, Saizo; Inoguchi, Shunsuke; Nishimoto, Mitsuhisa; Kikuchi, Takashi; Adomi, Shogo; Banno, Eri; De Velasco, Marco A.; Saito, Yoshitaka; Shimizu, Nobutaka; Mori, Yasunori; Minami, Takafumi; Fujita, Kazutoshi; Nozawa, Masahiro; Nose, Kazuhiro; Yoshimura, Kazuhiro; Uemura, Hirotsugu
• Is Part Of: Anti-cancer drugs. Volume 33:Issue 1(2022)
• Publication Date: 2022-01
• Subjects: disseminated intravascular coagulation -- ipilimumab -- nivolumab -- pazopanib -- renal cell carcinoma; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000001230
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Recently, combination therapy including immune checkpoint inhibition (ICI) has proven to be effective as first-line therapy for patients with metastatic renal cell carcinoma. Although the first-line combination therapies with ICI have shown clinical benefit, a number of patients require second-line treatment. We report a 60-year-old man with metastatic renal cell carcinoma who was treated with pazopanib soon after nivolumab plus ipilimumab combination therapy. He experienced Grade 3 disseminated intravascular coagulation (DIC). We suspect that this was caused by an interaction between pazopanib and nivolumab even though ICI therapy was discontinued. He was treated with thrombomodulin and platelet transfusion and recovered from DIC. Treatment with pazopanib was subsequently restarted. No evidence of DIC was observed thereafter. This severe adverse reaction may have been induced by an interaction between activated proinflammatory immune cells and cytokines from an exacerbated inflammatory state and pazopanib. This report highlights the need to perform careful monitoring of patients who receive molecular targeted therapy after ICI-based immunotherapy.